Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Centre, Randomised, Double-blind, Two-way Crossover Trial in Healthy Male Subjects Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven®

NCT02084810 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02084810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02084810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Centre, Randomised, Double-blind, Two-way Crossover Trial in Healthy Male Subjects Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven®
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Withdrawn
Start date
March 31, 2014
Completion date
July 31, 2014
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

congenital bleeding disorder, haemophilia a, haemophilia a with inhibitors, haemophilia b, haemophilia b with inhibitors, healthy